Elevance Health (ELV)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-05
$432.00-0.50%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-05
QuarterlyIQ Insights · ELV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks ELV against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75 3 .
Stated in 8 of 8 supplied quarters. Management reported: “We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75 3 .” “We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating efficiency, and Carelon’s value-based solutions.”
“We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75 3 .”
“We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider conne…”
“Document E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FIRST QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE • 1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 • 1Q 2026 dilut…”
“As we enter 2026, our focus is on advancing affordability and making healthcare easier to access and navigate for the members we serve.”
“In a dynamic healthcare environment, we’re focused on advancing affordability and elevating the member experience through our growing value-based care partnerships and AI-enabled digital solutions th…”
“While the external environment continues to evolve, we are focused on the areas within our control - managing healthcare costs, deploying targeted investments in advanced technology and value-based c…”
By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value fo…
Stated in 8 of 8 supplied quarters. Management reported: “By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders."” “Operating gain for Carelon totaled $1.1 billion, a decline of 3.8 percent year over year, reflecting the impact of lower health plan membership and continued investment in the expansion of risk-based capabilities in our Carelon Services business.”
By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value fo…
Stated in 8 of 8 supplied quarters. Management reported: “Medical membership of approximately 45.4 million as of March 31, 2026 increased by 186 thousand from year-end 2025, driven by expansion of our commercial fee-based membership, partially offset by anticipated reductions in our Medicare Advantage and Employer Group risk membership as we took disciplined action to reposition these businesses for sustainable performance.” “Through pricing discipline and targeted investments, we are strengthening the earnings power of our diversified platform and remain confident in our ability to return to at least 12% adjusted EPS growth in 2027."”
Document E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FIRST QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE • 1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 • 1Q 2026 dilut…
Stated in 4 of 8 supplied quarters. Management reported: “Medical membership of approximately 45.4 million as of March 31, 2026 increased by 186 thousand from year-end 2025, driven by expansion of our commercial fee-based membership, partially offset by anticipated reductions in our Medicare Advantage and Employer Group risk membership as we took disciplined action to reposition these businesses for sustainable performance.” “Through pricing discipline and targeted investments, we are strengthening the earnings power of our diversified platform and remain confident in our ability to return to at least 12% adjusted EPS growth in 2027."”
Manage medical costs and medical cost trends as part of the company's affordability focus and operating plan.
Over the trailing year it converted 0.62x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and red…”
““As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and accessible…”
“By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value fo…”
“We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider conne…”
“We are prioritizing targeted investments across clinical, operational, and administrative workflows to position the enterprise for long-term growth.”
“We maintained expense discipline while investing to support and strengthen our workforce, scale Carelon's capabilities, and accelerate technology adoption across the enterprise.”
“In a dynamic healthcare environment, we’re focused on advancing affordability and elevating the member experience through our growing value-based care partnerships and AI-enabled digital solutions th…”
“"In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across th…”
“In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and red…”
“As we look to 2025, we remain resolute in our goal to simplify the healthcare experience, deepen the impact of Carelon, and deploy innovative care models, positioning us to achieve sustainable growth…”
“By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value fo…”
“We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider conne…”
“Operating gain for Carelon totaled $1.1 billion, a decline of 3.8 percent year over year, reflecting the impact of lower health plan membership and continued investment in the expansion of risk-based…”
“We maintained expense discipline while investing to support and strengthen our workforce, scale Carelon's capabilities, and accelerate technology adoption across the enterprise.”
“The adjusted operating expense ratio was 10.4 percent, an increase of 100 basis points, primarily driven by targeted investments to scale Carelon’s capabilities, support and strengthen our workforce,…”
“With the embedded earnings power of our diversified Health Benefits and Carelon businesses, we remain confident in achieving at least 12% average annual growth in adjusted diluted EPS over time."”
“Through Carelon and our broader enterprise, we’re delivering on our strategy to be a lifetime trusted health partner—and elevating health beyond healthcare.””
“As we look to 2025, we remain resolute in our goal to simplify the healthcare experience, deepen the impact of Carelon, and deploy innovative care models, positioning us to achieve sustainable growth…”
“Document E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FIRST QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE • 1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 • 1Q 2026 dilut…”
“Document E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS; SETS FULL YEAR 2026 OUTLOOK • 4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 b…”
“Exhibit 99.1 E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS THIRD QUARTER 2025 RESULTS • Executing with discipline to improve affordability and elevate the member experience • 3Q 2025 operatin…”
“Document E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS FIRST QUARTER 2025 RESULTS • 1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 • 1Q 2025 adjusted operating gain 1 of $3…”